Longevity Peptides — Reference Comparison Card
SS-31 Phase 2/3 (PMID 31985937), Humanin decline ~30%/decade (PMID 27151978), Epitalon lifespan +13–24% rodent (PMID 14501183), GHK-Cu collagen synthesis human data (Grade B topical).
| Measure | Value | Unit | Notes |
|---|---|---|---|
| Peptides Compared | 5 | compounds | Epitalon, Humanin, SS-31, GHK-Cu, BPC-157 — representing telomere, mitochondrial, collagen, and tissue repair longevity pathways |
| Strongest Human Evidence | SS-31 (Grade B) | top-ranked | Only longevity peptide with Phase 2/3 clinical trial data (PMID 31985937); Phase 3 ongoing; FDA Breakthrough Therapy designation |
| Epitalon Rodent Lifespan | +13–24 | % lifespan extension | PMID 14501183: female SHR mice; strongest animal longevity signal in this group; no human RCT |
| Humanin Decline Rate | ~30 | % per decade after 40 | PMID 27151978: observational human data; no intervention trial shows clinical benefit from restoring levels |
| GHK-Cu Human Data | Yes — topical | evidence type | Grade B for topical skin applications (collagen synthesis, wound healing); Grade C for systemic effects |
| BPC-157 Human Evidence | None (Grade C) | grade | Extensive rodent tissue repair data; no published human RCTs; anecdotal clinical reports only |
Longevity Peptides — Reference Comparison
This page compares the five most-discussed longevity-oriented peptides: Epitalon, Humanin, SS-31 (Elamipretide), GHK-Cu, and BPC-157. Each targets a distinct biological pathway associated with aging.
Primary Comparison Table
| Peptide | Primary Longevity Mechanism | Evidence Grade | Human Data | Route | Availability |
|---|---|---|---|---|---|
| SS-31 (Elamipretide) | Cardiolipin stabilization; mitochondrial ETC coupling | B | Phase 2/3 clinical trials | IV infusion (trials) | Investigational only |
| GHK-Cu | Collagen synthesis; anti-inflammatory matrikine | B (topical) | Yes — human topical studies | Topical / SC (research) | Research chemical / cosmetic |
| Humanin | Mitochondrial-derived neuroprotection; anti-apoptotic | C | Observational (PMID 27151978) | SC (research only) | Research chemical |
| Epitalon | Telomerase activation; geroprotection | C | Limited Russian observational | SC / IV | Research chemical |
| BPC-157 | Anti-inflammatory; growth factor upregulation | C | Anecdotal; no RCT | SC or oral | Research chemical |
Mechanism Detail Table
| Peptide | Molecular Target | Pathway | Longevity Hypothesis |
|---|---|---|---|
| SS-31 | Cardiolipin (inner mitochondrial membrane) | ETC coupling → ATP efficiency | Mitochondrial bioenergetics decline = core aging driver; SS-31 reverses ETC uncoupling |
| GHK-Cu | Copper-peptide complex; ECM receptors | Collagen I/III synthesis; SPARC; VEGF | Tissue regeneration capacity declines with age; GHK-Cu restores ECM repair signaling |
| Humanin | FPRL1/FPR2; CNTFR; gp130 | JAK/STAT; PI3K/Akt; Bcl-2 | Endogenous neuroprotective signal declines with age; lower levels = higher disease risk |
| Epitalon | Telomerase (TERT component activation) | Telomere maintenance | Telomere attrition = cellular senescence; epitalon restores telomerase activity (in vitro) |
| BPC-157 | VEGFR; EGF; dopamine D1/D2 | Growth factor upregulation | Tissue repair capacity declines; BPC-157 maintains regenerative signaling |
Evidence Depth Table
| Peptide | Rodent Evidence | Human Observational | Human RCT | Regulatory Status |
|---|---|---|---|---|
| SS-31 | Strong — cardiolipin, heart failure models | Yes — disease populations | Yes — Phase 2/3 (PMID 31985937) | FDA Breakthrough Therapy (Barth syndrome) |
| GHK-Cu | Yes — wound healing, collagen | Yes — topical skin studies | Limited (topical only) | Cosmetic ingredient; no therapeutic approval |
| Humanin | Yes — neuroprotection, AD models | Yes — age-related decline (PMID 27151978) | None | None |
| Epitalon | Yes — lifespan 13–24% (PMID 14501183) | Small Russian observational | None (Western) | None |
| BPC-157 | Extensive — gut, tendon, CNS | Anecdotal only | None | None |
Accessible vs Investigational
| Peptide | Accessible via Research Chemical Vendors? | Price Range (typical) |
|---|---|---|
| Epitalon | Yes | Moderate (tetrapeptide synthesis) |
| Humanin | Yes (limited suppliers) | High (21 aa synthesis) |
| GHK-Cu | Yes (widespread) | Low–Moderate |
| BPC-157 | Yes (widespread) | Moderate |
| SS-31 (Elamipretide) | No — investigational pharmaceutical | Not available commercially |
Evidence Grade Callout
Grade B: SS-31 (clinical trials, disease populations); GHK-Cu (topical collagen/wound healing). Grade C: Humanin (observational human + animal), Epitalon (rodent lifespan + limited Russian human), BPC-157 (rodent tissue repair).
No longevity peptide in this group has Grade A evidence for anti-aging or longevity endpoints in healthy humans.
Legal Disclaimer
None of these peptides is FDA, EMA, TGA, or Health Canada approved for longevity or anti-aging use. SS-31 is an investigational pharmaceutical only accessible via clinical trials. The others are research chemicals in most jurisdictions. This reference card is educational only and does not constitute medical advice.
Related Pages
Sources
- Steele HE et al. Elamipretide (SS-31) improves mitochondrial function in Barth syndrome. JACC Basic Transl Sci. 2020;5(1):11-22. PMID 31985937
- Cobb LJ et al. Mitochondrial-derived peptides are age-dependent regulators. Commun Biol. 2016;1:19. PMID 27151978
- Anisimov VN et al. Effect of Epitalon on biomarkers of aging in SHR mice. Biogerontology. 2003;4(4):193-202. PMID 14501183
Frequently Asked Questions
Which longevity peptide has the most clinical evidence?
SS-31 (elamipretide) has the strongest human evidence base in this group, with completed Phase 2 trials in Barth syndrome (PMID 31985937) and HFpEF, and ongoing Phase 3 trials. It has FDA Breakthrough Therapy designation. It is the only longevity-adjacent peptide with a robust, registered, peer-reviewed clinical trial program. However, it is an investigational pharmaceutical and is not available outside clinical trials. For commercially available peptides, GHK-Cu has the strongest evidence — but only for topical application (collagen synthesis and wound healing; Grade B).
Does any longevity peptide have proven human anti-aging effects?
No longevity peptide has demonstrated anti-aging benefit in a well-powered, pre-registered human RCT with validated aging endpoints. Lifespan extension data exists only in rodent models (Epitalon: PMID 14501183). Human data is either observational (Humanin age-related decline: PMID 27151978), disease-specific (SS-31 in Barth syndrome, HFpEF), or topical (GHK-Cu). The gap between compelling animal/cell data and proven human longevity benefit is large, and no compound has crossed it yet.
Can these peptides be stacked for longevity?
There is no evidence base for combining longevity peptides. Each peptide operates through distinct mechanisms (telomerase, mitochondrial cardiolipin, MDP signaling, collagen synthesis) that are not obviously synergistic or additive. Combining research-stage compounds without human safety data multiplies unknown risks without evidence of multiplied benefit. This is an area of active interest in the biohacking community but has no clinical or scientific support.